Skip to content

SILO PHARMA, INC.: 10-Q filed 2026-08-13

What SILO PHARMA, INC. reported in its quarterly report filed 2026-08-13 (fiscal Q2 2026): 36 published measures, 106 facts as tagged in accession 0001213900-26-089085.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-13
Fiscal period
fiscal Q2 2026
Accession
0001213900-26-089085 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SILO PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-305,952,023USD
At 2025-12-317,605,100USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-301,065,733USD
At 2025-12-311,299,659USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-304,886,290USD
At 2026-03-315,681,836USD
At 2025-12-316,305,441USD
At 2025-06-304,917,083USD
At 2025-03-314,011,113USD
At 2024-12-315,034,265USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-303,277,095USD
At 2025-12-314,748,700USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-832,829USD91
2026-01-01 to 2026-06-30-2,479,946USD181
2026-01-01 to 2026-03-31-1,647,117USD90
2025-04-01 to 2025-06-30-1,204,293USD91
2025-01-01 to 2025-06-30-2,235,730USD181
2025-01-01 to 2025-03-31-1,031,437USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-1,604,484USD181
2025-01-01 to 2025-06-30-2,925,568USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-01-01 to 2026-06-3018,026USD181
2025-04-01 to 2025-06-3018,025USD91
2025-01-01 to 2025-06-3036,051USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-26,997USD181
2025-01-01 to 2025-06-302,093,958USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30159,876USD181
2025-01-01 to 2025-06-301,259,483USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-21,972,335USD
At 2025-12-31-19,492,389USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,098,517shares91
2026-01-01 to 2026-06-301,006,743shares181
2025-04-01 to 2025-06-30418,649shares91
2025-01-01 to 2025-06-30359,172shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,098,517shares91
2026-01-01 to 2026-06-301,006,743shares181
2025-04-01 to 2025-06-30418,649shares91
2025-01-01 to 2025-06-30359,172shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.76USD/shares91
2026-01-01 to 2026-06-30-2.46USD/shares181
2025-04-01 to 2025-06-30-2.88USD/shares91
2025-01-01 to 2025-06-30-6.22USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.76USD/shares91
2026-01-01 to 2026-06-30-2.46USD/shares181
2025-04-01 to 2025-06-30-2.88USD/shares91
2025-01-01 to 2025-06-30-6.22USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-3095,793USD181
2025-01-01 to 2025-06-3017,445USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-928,949USD91
2026-01-01 to 2026-06-30-2,523,609USD181
2025-04-01 to 2025-06-30-1,248,551USD91
2025-01-01 to 2025-06-30-2,342,672USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-305,713,526USD
At 2025-12-317,387,725USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-301,065,733USD
At 2025-12-31650,183USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-30928,949USD91
2026-01-01 to 2026-06-302,520,947USD181
2025-04-01 to 2025-06-301,265,117USD91
2025-01-01 to 2025-06-302,375,804USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-2,662USD181
2025-04-01 to 2025-06-3016,566USD91
2025-01-01 to 2025-06-3033,132USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2026-01-01 to 2026-06-3020,688USD181
2025-04-01 to 2025-06-301,459USD91
2025-01-01 to 2025-06-302,919USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-30298,418USD91
2026-01-01 to 2026-06-301,311,683USD181
2025-04-01 to 2025-06-30717,247USD91
2025-01-01 to 2025-06-301,311,209USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-301,128,610shares
At 2025-12-31887,886shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-303,277,095USD
At 2025-12-314,748,700USD
At 2025-06-304,333,672USD
At 2024-12-313,905,799USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3026,851,682USD
At 2025-12-3125,791,913USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-306,830USD
At 2025-12-315,828USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-06-30211,500USD
At 2025-12-31217,375USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30280,870USD
At 2025-12-31208,559USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2026-04-0133,240USD
At 2025-12-3172,102USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-832,829USD91
2026-01-01 to 2026-06-30-2,479,946USD181
2025-04-01 to 2025-06-30-1,204,293USD91
2025-01-01 to 2025-06-30-2,235,730USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-834,720USD91
2026-01-01 to 2026-06-30-2,478,944USD181
2025-04-01 to 2025-06-30-1,205,433USD91
2025-01-01 to 2025-06-30-2,228,585USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2026-01-01 to 2026-06-305,875USD181
2025-01-01 to 2025-06-305,565USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,865USD91
2026-01-01 to 2026-06-306,238USD181
2025-04-01 to 2025-06-301,648USD91
2025-01-01 to 2025-06-303,714USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-3096,120USD91
2026-01-01 to 2026-06-3043,663USD181
2025-04-01 to 2025-06-3044,258USD91
2025-01-01 to 2025-06-30106,942USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-306,238USD181
2025-01-01 to 2025-06-303,714USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,593,897USD181

Inspect the source

Entity
SILO PHARMA, INC. / CIK 0001514183
Captured
2026-09-20T09:13:20.337Z
SEC response SHA-256
b55b01ff5b31c52a933a54029f5fe837eae02333bd43de16acad37f51e3b67db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514183.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))